{"version":"1.0","provider_name":"Cancer Research Institute","provider_url":"https:\/\/www.cancerresearch.org\/es","title":"CRI Launches Pioneering Phase 2\/3 Trial Using Labcorp Liquid Biopsy to Guide Precision Immunotherapy for Lung Cancer\u00a0 - Cancer Research Institute","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Coju8f09rz\"><a href=\"https:\/\/www.cancerresearch.org\/es\/media-room\/labcorp-cri-br36\">CRI Launches Pioneering Phase 2\/3 Trial Using Labcorp Liquid Biopsy to Guide Precision Immunotherapy for Lung Cancer\u00a0<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.cancerresearch.org\/es\/media-room\/labcorp-cri-br36\/embed#?secret=Coju8f09rz\" width=\"600\" height=\"338\" title=\"\u00abCRI Launches Pioneering Phase 2\/3 Trial Using Labcorp Liquid Biopsy to Guide Precision Immunotherapy for Lung Cancer\u00a0\u00bb \u2014 Cancer Research Institute\" data-secret=\"Coju8f09rz\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.cancerresearch.org\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/CRI_Logo_Primary_RGB_P1.jpg","thumbnail_width":1050,"thumbnail_height":587,"description":"The Cancer Research Institute (CRI) is pleased to announce the enrollment of the first patient in the second stage of BR.36 (NCT04093167), a Phase 2\/3 clinical trial using circulating tumor DNA (ctDNA) \u2013 tiny DNA fragments shed by dying cancer cells \u2013 to measure early responses to immunotherapy and guide treatment decisions for advanced lung cancer patients.\u00a0"}